Long-term gluten intake is not associated with cognitive scores in middle-aged women without celiac disease, according to a study published online May 21 in JAMA Network Open.
Clinical-stage company ImmusanT’s therapeutic vaccine candidate Nexvax2 has been granted fast track designation by the US Food and Drug Administration (FDA).
Biopharmaceutical company Provention Bio has agreed to further develop Amgen’s AMG 714 drug candidate for the treatment of gluten-free diet non-responsive celiac disease (NRCD).